Department of Clinical Oncology and Nuclear Medicine, Kafrelsheikh University,Egypt.
Department of General and Paediatric Surgery, Kafrelsheikh University,Egypt.
J Pak Med Assoc. 2023 Apr;73(Suppl 4)(4):S200-S204. doi: 10.47391/JPMA.EGY-S4-40.
To examine the chemokine receptor type 1 expression in breast cancer tissues before and after neoadjuvant chemotherapy, and its relationship with pathological response to neoadjuvant chemotherapy and other clinical variables.
The prospective study was conducted at Kafrelsheikh University Hospital, Egypt, from November 2018 to March 2021, and comprised female patients with new histopathologically proven breast cancer eligible for chemotherapy. Paraffin blocks of tumourspecimens were stained immunohistochemically using concentrated rabbit anti-human chemokine receptor type 1 polyclonal antibody kits. The patients were followed up for treatment response, disease recurrence and mortality. Data was analysed using SPSS 25.
Of the 100 patients with mean age 50.2±12.1 years, 40(40%) in group A with mean age 55.1±9.3 showed marked response and 60(60%) in group B with mean age 47.0±12.7 yearsshowed mild/moderate response (p<0.001). Group A patients had significantly lower baseline and post-treatment chemokine receptor type 1 expression compared to group B patients (p<0.05). The change in chemokine receptor type 1 expression was not significantly different (p>0.05). Patients with tumour grade 3 had significantly higher baseline chemokine receptor type 1 expression compared to patients with tumour grade 2. Tumourstage and post-treatment chemokine receptor type 1 expression were also significantly interlinked (p<0.05). Multivariate regression analysisidentified patients'age, baseline chemokine receptor type 1 and post-treatment chemokine receptor type 1 expressions as predictors of treatment response.
There was found to be an association between baseline and post-treatment chemokine receptor type 1 expression in breast cancer tissues and pathological response to neoadjuvant chemo therapy in such patients.
检测新辅助化疗前后乳腺癌组织中趋化因子受体 1 型的表达及其与新辅助化疗病理反应和其他临床变量的关系。
这项前瞻性研究于 2018 年 11 月至 2021 年 3 月在埃及卡夫拉谢赫大学医院进行，纳入了新病理确诊为乳腺癌且有化疗适应证的女性患者。使用浓缩兔抗人趋化因子受体 1 多克隆抗体试剂盒对肿瘤标本的石蜡块进行免疫组织化学染色。对患者进行随访，观察治疗反应、疾病复发和死亡率。使用 SPSS 25 进行数据分析。
在 100 名平均年龄为 50.2±12.1 岁的患者中，40 名（40%）年龄为 55.1±9.3 岁的患者在组 A 中表现出明显的反应，60 名（60%）年龄为 47.0±12.7 岁的患者在组 B 中表现出轻度/中度反应（p<0.001）。与组 B 患者相比，组 A 患者的基线和治疗后趋化因子受体 1 表达明显较低（p<0.05）。趋化因子受体 1 表达的变化无显著差异（p>0.05）。肿瘤分级为 3 级的患者与肿瘤分级为 2 级的患者相比，基线趋化因子受体 1 表达明显较高。肿瘤分期和治疗后趋化因子受体 1 表达也有显著关联（p<0.05）。多变量回归分析确定患者年龄、基线趋化因子受体 1 和治疗后趋化因子受体 1 表达是治疗反应的预测因子。
在新辅助化疗的乳腺癌组织中，发现了趋化因子受体 1 型的基线和治疗后表达与病理反应之间存在关联。
